Polyzos SA, Kountouras J, Romiopoulos I, Polymerou V

Language: English
References: 10
Page: 150-151
PDF size: 64.83 Kb.

Text Extraction

Dear Editor:

We read with interest the study of Genc, et al. showing similar plasma visfatin levels between men with nonalcoholic fatty liver disease (NAFLD) and healthy controls of lower body mass index (BMI) and waist circumference (WC). Furthermore, visfatin was similar in different grades of steatosis, ballooning and lobular inflammation or stages of fibrosis. Interestingly, visfatin was negatively correlated with tumor necrosis factor (TNF)-α, but not with interleukin (IL)-6, high-sensitivity C-reactive protein (hsCRP) or adiponectin.

REFERENCES

1. Genc H, Dogru T, Kara M, Tapan S, Ercin CN, Acikel C, Karslioglou Y, et al. Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. Ann Hepatol 2013; 12: 308-87.

2. Polyzos S, Kountouras J, Papatheodorou A, Katsiki E, Patsiaoura K, Zafeiriadou E, Zavos C, et al. Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease -Introduction of CHA index. Ann Hepatol 2013; 12: 749-57.

3. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, Fang Y, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27: 412-21.

4. Dahl TB, Haukeland JW, Yndestad A, Ranheim T, Gladhaug IP, Damas JK, Haaland T, et al. Intracellular nicotinamide phosphoribosyltransferase protects against hepatocyte apoptosis and is down-regulated in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2010; 95: 3039-47.

5. Yoon MY, Sung JM, Song CS, Lee WY, Rhee EJ, Shin JH, Yoo CH, et al. Enhanced A-FABP expression in visceral fat: potential contributor to the progression of NASH. Clin Mol Hepatol 2012; 18: 279-86.

6. Auguet T, Terra X, Porras JA, Orellana-Gavalda JM, Martinez S, Aguilar C, Lucas A, et al. Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease. Clin Biochem 2013; 46: 202-8.

7. Aller R, de Luis DA, Izaola O, Sagrado MG, Conde R, Velasco MC, Alvarez T, et al. Influence of Visfatin on Histopathological Changes of Non-alcoholic Fatty Liver Disease. Dig Dis Sci 2009; 54: 1772-7.

8. Kukla M, Ciupinska-Kajor M, Kajor M, Wylezol M, Zwirska- Korczala K, Hartleb M, Berdowska A, et al. Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery. Pol J Pathol 2010; 61: 147-53.

9. Moschen AR, Gerner RR, Tilg H. Pre-B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity-related disorders. Curr Pharm Des 2010; 16: 1913-20.

10. Montecucco F, Cea M, Bauer I, Soncini D, Caffa I, Lasiglie D, Nahimana A, et al. Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience. Curr Drug Targets 2013; 14: 637-43.